Development of new therapeutics effective in fighting infectious diseases remains critical in this age of multiple drug resistance, bioterrorism and the introduction of evolving infectious organisms. Research in the Anderson lab focuses on the design of new drugs for infectious diseases. Current projects include the design of anti-protozoal, antibacterial, and antifungal compounds that will be effective against Cryptosporidium, Bacillus anthracis, Staphylococcus aureus (MRSA), Candida albicans and Candida glabrata infections. Work in the laboratory is multi-disciplinary and incorporates many of the processes of early-stage drug development: protein structure determination by various techniques, computational modeling of protein:inhibitor interactions, enzyme inhibition and cell growth inhibition.